

Iconic Labs PLC

("Iconic" or the "Company")

Conversion of Notes and Allotment of Shares

Iconic Labs PLC (LSE:ICON), announces that it has received a valid Conversion Notice from David Sefton.

The Conversion Notice was dated 28 May 2025 and provides for 1 Convertible Note to be converted into 195,312 ordinary shares of £0.0001 in the Company ("Ordinary Shares") at a conversion price of GBP 0.0256 at the aggregate principal amount of £5,000.

Application is therefore being made for an aggregate of 195,312 new Ordinary Shares to be admitted to trading on the Main Market of the London Stock Exchange which is expected to be on or around 3 June 2025. These shares rank pari passu with the existing Ordinary Shares of the Company.

Following the issue of these shares, the Company's issued ordinary share capital shall consist of 11,356,795 Ordinary Shares. The figure of 11,356,795 represents the total voting rights in the Company and should be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance & Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

For any further information or enquiries please contact:

Iconic Labs

John Farquharson, Interim Chief Executive Officer

via Yellow Jersey PR

Novum Securities Limited

David Coffman / Daniel Harris

Tel: +44 (0) 20 7399 9400

Yellow Jersey PR

Charles Goodwin

Annabelle Wills

Bessie Elliot

Tel: +44 (0) 20 3004 9512

iconic@yellowjerseypr.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CONAPMFTMTTBMA